证券代码：688690 证券简称：纳微科技 公告编号：2025-019 苏州纳微科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截至本公告日，苏州纳微科技股份有限公司（以下简称"公司"）股东苏州 纳卓管理咨询合伙企业（有限合伙）（以下简称"苏州纳卓"）持有公司股份 14,250,000 股，占公司总股本的 3.5288%，其中无限售条件的流通股 14,250,000 股；苏州纳研管理咨询合伙企业（有限合伙）（以下简称"苏州纳研"）持有公 司股份 28,500,000 股，占公司总股本的 7.0577%，其中无限售条件的流通股 28,500,000 股。上述股份为公司首次公开发行前取得的股份，并已于 2024 年 6 月 24 日起上市流通。 减持计划的主要内容 公司近日收到股东苏州纳卓及苏州纳研发出的《关于减持公司股份的告知 函》。因持股员工自身资金需求，苏州纳卓及苏州纳研拟自本公告披露之日起 15 个交易日后的 3 个月内通过集中竞价 ...

Core Viewpoint - The IVD industry is experiencing a significant downturn in revenue and profits, with over 70% of companies reporting a year-on-year decline in revenue and more than half facing losses or drastically reduced profits [2][5]. Revenue and Profit Trends - In Q1 2025, major IVD companies such as Mindray Medical, Dian Diagnostics, and RunDa Medical reported substantial declines in both revenue and net profit, with Mindray's revenue at 8.237 billion yuan (down 12.12%) and net profit at 2.629 billion yuan (down 16.81%) [2][4]. - Among 60 IVD companies analyzed, 16 reported revenue growth, with 8 achieving both revenue and net profit growth [2]. Market Challenges - The IVD sector is facing multiple challenges, including a slowdown in the conventional medical testing market, stricter cost control policies in healthcare, and the impact of centralized procurement policies [5][6]. - The anticipated centralized procurement in 28 provinces is expected to further pressure IVD companies, particularly in the high-volume chemical luminescence market [6]. Company Strategies and Innovations - Some companies are adapting by focusing on niche markets and innovative product offerings, such as New Industry and Sansure Bio, which reported revenue growth of 10.12% and 21.62% respectively in Q1 2025 [9]. - Companies are also exploring international markets, with Mindray's overseas revenue reaching 16.43 billion yuan in 2024, accounting for 44.75% of total revenue [9][10]. Technological Advancements - The IVD industry is witnessing a shift towards digitalization and AI integration, with partnerships like that of BGI and Dian Diagnostics aiming to enhance diagnostic efficiency and precision [10][11]. - The emergence of AI technologies is reshaping the IVD landscape, although challenges remain in data integration and commercialization [11].

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to see a profit turning point due to high profitability and gradual release of profit elasticity. The gross profit margin for 2024 is projected at 70.22%, a year-on-year decrease of 7.85 percentage points, primarily due to the lower margin impact from the consolidation of Fuli Instruments. The core products, chromatography fillers and chromatography media, maintain a gross profit margin of 81.56%, with a slight year-on-year decline of 2.39 percentage points. The company’s unique ability to self-produce core raw materials, microspheres, is expected to further highlight its competitive edge, supporting a high level of gross margin for core products [2][4]. Financial Performance - In 2024, the company achieved revenue of 782 million yuan, a year-on-year increase of 33.33%. The net profit attributable to the parent company was 82.84 million yuan, up 20.82% year-on-year. In Q1 2025, the company reported revenue of 189 million yuan, a year-on-year growth of 22.39%, and a net profit of 29.22 million yuan, reflecting a 72.98% increase year-on-year [9][11]. Growth Potential - The company is positioned to benefit from accelerated domestic substitution and its own product strength and platform-driven growth. The core business of chromatography fillers and chromatography media is expected to continue its growth trend, with Q1 2025 revenue reaching approximately 111 million yuan, a year-on-year increase of about 10.62%. The strategic focus on high-quality clients is anticipated to further enhance operational quality [4][9]. Earnings Forecast and Valuation - The company’s revenue is projected to reach 966 million yuan in 2025, with a year-on-year growth of 23.44%. The net profit attributable to the parent company is expected to be 139 million yuan, reflecting a significant year-on-year increase of 68.00%. The earnings per share (EPS) for 2025 is estimated at 0.34 yuan, with a price-to-earnings (P/E) ratio of 66 times based on the closing price on May 8, 2025 [4][11].

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to see a profit turning point due to high profitability and gradual release of profit elasticity, despite a slight decline in gross margin to 70.22% in 2024 [2] - The company has a strong cash flow generation capability, with a net cash flow from operating activities of 133 million yuan in 2024, indicating good operational quality [3] - The company is positioned to benefit from domestic substitution trends and has built a unique "product + service" platform, which is expected to drive growth in the coming years [4] Summary by Sections Profitability - The gross margin for 2024 is projected at 70.22%, down 7.85 percentage points year-on-year, primarily due to the lower margin impact from the consolidation of Fuli Instruments. The core products, chromatography fillers and chromatography media, maintain a gross margin of 81.56%, with a slight year-on-year decline of 2.39 percentage points [2] - The company’s high R&D investment has led to a sufficient reserve of new products, which can help mitigate risks from intensified market competition [2] Operational Quality - The net cash flow from operating activities for 2024 is expected to be 133 million yuan, reflecting a year-on-year increase of 5.99%, indicating sustained operational quality [3] - The accounts receivable turnover days for 2024 are 117 days, shortened by approximately 14 days year-on-year, while the first quarter of 2025 shows an increase to 145 days, likely due to a higher proportion of longer-term instrument products [3] Earnings Forecast and Valuation - The company is expected to achieve revenues of 966 million yuan in 2025, growing by 23.44% year-on-year, and a net profit attributable to shareholders of 139 million yuan, representing a growth of 68.00% [4] - The projected earnings per share (EPS) for 2025 is 0.34 yuan, with a price-to-earnings (P/E) ratio of 66 times based on the closing price on May 8, 2025 [4]

Group 1 - The company reported a revenue of 782 million yuan for 2024, representing a year-on-year growth of 33.33%, with a net profit attributable to the parent company of 83 million yuan, up 20.82% year-on-year [1] - In Q1 2025, the company achieved a revenue of 189 million yuan, a year-on-year increase of 22.39%, and a net profit attributable to the parent company of 29 million yuan, up 72.98% year-on-year [1] - The core business of chromatography fillers and media generated a revenue of 451 million yuan in 2024, with a year-on-year growth of 10.20% [2] Group 2 - The newly added chromatography analysis instruments and accessories contributed a revenue of 154 million yuan, primarily from the consolidation of the acquired company Fuli Instruments [2] - The market for chromatography fillers is expanding, with a current domestic market penetration rate of only about 10%, indicating significant potential for domestic substitution [3] - The company has established strategic cooperation agreements with five major clients, resulting in a sales volume of 224 million yuan, accounting for 50% of the revenue from chromatography fillers [3] Group 3 - The company is evolving into a leading domestic supplier of chromatography fillers, consumables, and instruments, driven by underlying technology [4] - Revenue projections for 2025-2027 are 977 million yuan, 1.17 billion yuan, and 1.37 billion yuan, with net profits of 134 million yuan, 203 million yuan, and 290 million yuan respectively [4] - The current stock price corresponds to a PE ratio of 67, 45, and 31 times for 2025-2027 [4]

Core Viewpoint - Nanwei Technology has been covered for the first time with a "Buy" rating and a target price of 29.2 yuan, indicating strong growth potential in the domestic market for chromatography materials and instruments [1]. Financial Performance - In 2024, the company achieved revenue of 782 million yuan, a year-on-year increase of 33.33%, and a net profit attributable to shareholders of 83 million yuan, up 20.82%. The non-recurring net profit was 66 million yuan, showing a significant growth of 108.55% [2]. - For Q1 2025, the company reported revenue of 189 million yuan, a year-on-year increase of 22.39%, and a net profit attributable to shareholders of 29 million yuan, up 72.98%. The non-recurring net profit was 25 million yuan, reflecting an 85.28% increase [2]. Business Segments - The core business of chromatography fillers and media generated revenue of 451 million yuan in 2024, a growth of 10.20%. The revenue from large molecule chromatography media was 249 million yuan, flat year-on-year, while small molecule chromatography fillers saw a 16.13% increase to 165 million yuan [3]. - The newly added chromatography analysis instruments and accessories contributed 154 million yuan, primarily from the acquisition of Fuli Instruments. Revenue from protein chromatography systems and accessories decreased by 33.41% to 40 million yuan, while liquid chromatography columns and sample pretreatment products increased by 26.15% to 73 million yuan [3]. Market Dynamics - The chromatography filler market is expanding, driven by the growth of biopharmaceuticals and peptide drugs. Currently, the market is dominated by imported manufacturers, with domestic market share at only about 10%. The emphasis on cost reduction and supply chain security is accelerating domestic substitution [4]. - The company has established a comprehensive product layout and has gained recognition from leading domestic pharmaceutical companies. In 2024, the number of customers increased to 792, with strategic cooperation agreements signed with five new clients [4]. Investment Outlook - The company is evolving into a leading domestic supplier of chromatography fillers, consumables, and instruments, benefiting from ongoing domestic substitution and a robust project pipeline. Revenue projections for 2025-2027 are 977 million, 1.17 billion, and 1.37 billion yuan, with net profits of 134 million, 203 million, and 290 million yuan respectively [5].

中信证券股份有限公司 关于苏州纳微科技股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对苏州纳微科技股份有限公司（以下简称"纳微科技""公司" "上市公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本持续 督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如 下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 王琦、王栋 （三）现场检查人员 王琦、楚合玉 （四）现场检查时间 2025 年 4 月 25 日 现场检查人员对本持续督导期内公司治理和内部控制情况、信息披露情况、 公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、募集资 金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面进行了 现场检查，具体检查内容详见本报告"二、本次现场检查主要事项及意见"。 1 （六）现场检查手段 本次现场检查的手段主要包括资料查阅、访谈、现场查看等，具体检查手段 详见" ...

苏州纳微科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688690 证券简称：纳微科技 苏州纳微科技股份有限公司 2024年年度股东大会 2024 年年度股东大会会议须知 1 苏州纳微科技股份有限公司 2024 年年度股东大会会议资料 会议资料目录 | 2024 年年度股东大会会议须知 3 | | | --- | --- | | 2024 年年度股东大会会议议程 5 | | | 一、会议时间、地点及投票方式 | 5 | | 二、会议议程 | 5 | | 2024 年年度股东大会会议议案 7 | | | 议案一：关于公司《2024 年年度报告》及摘要的议案 7 | | | 议案二：关于公司 2024 年度财务决算报告和 2025 年度财务预算报告的议案 | 8 | | 议案三：关于公司 2024 年度董事会工作报告的议案 | 11 | | 议案四：关于公司 2024 年度监事会工作报告的议案 | 22 | | 议案五：关于公司 2024 年度独立董事述职报告的议案 | 28 | | 议案六：关于公司 2024 年度利润分配方案的议案 | 29 | | 议案七：关于确认 2024 年度日常关联交易 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-018 苏州纳微科技股份有限公司 关于参加2024年度科创板创新药行业集体业绩说明会 暨2025年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 8 日(星期四) 下午 15:00-17:00 （二）会议召开地点：上证路演中心（http://roadshow.sseinfo.com） （三）会议召开方式：线上文字互动 三、 参加人员 董事长：江必旺博士 （http://roadshow.sseinfo.com） 会议召开方式：线上文字互动 会议问题征集：投资者可于 5 月 7 日（周三）16:00 前登录上证路演中心 网站首页，点击"提问预征集"栏目进行提问或通过公司投资者关系邮箱 （ir@nanomicro.com）将需要了解和关注的问题提前提供给公司。公司将在文字互 动环节对投资者普遍关注的问题进行回答。 苏州纳微科技股份有限公司（以下简称"公 ...

盈利能力分析 近期纳微科技(688690)发布2025年一季报，证券之星财报模型分析如下： 财务概况 纳微科技(688690)在2025年第一季度实现了营业总收入1.89亿元，同比增长22.39%；归母净利润达到 2921.54万元，同比增长72.98%；扣非净利润为2507.61万元，同比增长85.28%。这表明公司在报告期内 盈利能力有所增强。 成本与费用控制 公司的销售费用、管理费用、财务费用总计为6214.08万元，三费占营收比为32.95%，同比下降了4.98 个百分点。这表明公司在费用控制方面有所改善。 现金流与资产负债 应收账款状况 公司应收账款为2.94亿元，同比增长14.69%。值得注意的是，应收账款与利润的比例达到了354.71%， 建议投资者密切关注应收账款的回收情况，以评估潜在的坏账风险。 商业模式与资本运作 纳微科技的业绩主要依赖于研发及营销驱动。公司自上市以来，累计融资总额为5.52亿元，累计分红总 额为9019.40万元，分红融资比为0.16。这表明公司在资本运作方面较为稳健，但仍需关注其研发投入和 市场推广的效果。 综上所述，纳微科技在2025年第一季度表现出较强的盈利能力和费 ...